Literature DB >> 25150165

Planned neck dissection after chemoradiotherapy in advanced oropharyngeal squamous cell cancer: the role of US, MRI and FDG-PET/TC scans to assess residual neck disease.

Raul Pellini1, Valentina Manciocco1, Mario Turri-Zanoni2, Antonello Vidiri3, Giuseppe Sanguineti4, Laura Marucci4, Rosa Sciuto5, Renato Covello6, Isabella Sperduti7, Ramy Kayal3, Vincenzo Anelli3, Barbara Pichi1, Giuseppe Mercante1, Giuseppe Spriano1.   

Abstract

OBJECTIVE: To investigate the ability of neck ultrasounds (US), magnetic resonance imaging (MRI) and positron emission tomography (FDG-PET/TC) in detecting residual nodal disease after chemoradiotherapy in patients with advanced oropharyngeal squamous cell carcinoma (OPSCC).
METHODS: From 2006 to 2009, 36 consecutive patients affected by OPSCC with bulky nodal disease (>3 cm), treated with primary concurrent chemoradiotherapy, were enrolled prospectively. Nodal response to treatment was assessed by using US, MRI and FDG-PET/CT. Planned neck dissection (ND) was performed in all the patients, and the histopathological node status was compared to the imaging findings in order to establish sensitivity, specificity, accuracy and predictive values of each technique.
RESULTS: Metastatic disease was assessed in 18/37 (48.6%) hemi-necks, always localized in levels II-IV. US showed greater sensitivity (77.8%) and, combined with FDG-PET/TC, produced the highest negative predictive value (93.3%). US, MRI and FDG-PET/TC scans showed the highest specificity (100%), accuracy (93.8%) and positive predictive values (100%).
CONCLUSIONS: In the presence of advanced OPSCC with bulky nodal disease, US combined with FDG-PET/TC could be a reliable and cost-effective strategy to identify patients with complete nodal response to chemoradiotherapy that might not require post-treatment ND but only observation. When residual disease in the neck was detected, selective ND was recommended.
Copyright © 2014 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chemoradiotherapy; FDG-PET–CT; Neck ultrasound; Oropharyngeal cancer; Planned neck dissection

Mesh:

Substances:

Year:  2014        PMID: 25150165     DOI: 10.1016/j.jcms.2014.06.023

Source DB:  PubMed          Journal:  J Craniomaxillofac Surg        ISSN: 1010-5182            Impact factor:   2.078


  5 in total

1.  Qualitative interpretation of PET scans using a Likert scale to assess neck node response to radiotherapy in head and neck cancer.

Authors:  Johanna Sjövall; Ulrika Bitzén; Elisabeth Kjellén; Per Nilsson; Peter Wahlberg; Eva Brun
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-10-02       Impact factor: 9.236

2.  Post-treatment 18F-FDG-PET/CT versus contrast-enhanced CT in patients with oropharyngeal squamous cell carcinoma: comparative effectiveness study.

Authors:  Mehdi Taghipour; Esther Mena; Matthew J Kruse; Sara Sheikhbahaei; Rathan M Subramaniam
Journal:  Nucl Med Commun       Date:  2017-03       Impact factor: 1.690

3.  No benefit for regional control and survival by planned neck dissection in primary irradiated oropharyngeal cancer irrespective of p16 expression.

Authors:  R Maquieira; S K Haerle; G F Huber; A Soltermann; S R Haile; S J Stoeckli; Martina A Broglie
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-06-10       Impact factor: 2.503

Review 4.  Assessing Novel Drugs and Radiation Technology in the Chemoradiation of Oropharyngeal Cancer.

Authors:  Agostino Cristaudo; Mitchell Hickman; Charles Fong; Paul Sanghera; Andrew Hartley
Journal:  Medicines (Basel)       Date:  2018-06-27

5.  Response evaluation of cervical lymph nodes after chemoradiation in patients with head and neck cancer - does additional [18F]FDG-PET-CT help?

Authors:  Daniel Dejaco; Christian Uprimny; Gerlig Widmann; David Riedl; Patrizia Moser; Christoph Arnold; Teresa Bernadette Steinbichler; Barbara Kofler; Volker Hans Schartinger; Irene Virgolini; Herbert Riechelmann
Journal:  Cancer Imaging       Date:  2020-09-29       Impact factor: 3.909

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.